Shares of GeoVax Labs Inc. (NASDAQ:GOVX – Get Free Report) have been assigned a consensus recommendation of “Buy” from the five brokerages that are presently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $8.88.
A number of research analysts have recently commented on the stock. Alliance Global Partners dropped their price objective on shares of GeoVax Labs from $15.00 to $8.50 and set a “buy” rating for the company in a research note on Tuesday, April 15th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research note on Wednesday, April 16th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price objective on shares of GeoVax Labs in a research note on Thursday. Finally, Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, July 13th.
Read Our Latest Report on GeoVax Labs
GeoVax Labs Trading Up 4.0%
GeoVax Labs (NASDAQ:GOVX – Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.14. GeoVax Labs had a negative net margin of 438.20% and a negative return on equity of 511.96%. The company had revenue of $1.64 million during the quarter, compared to the consensus estimate of $0.75 million. As a group, research analysts predict that GeoVax Labs will post -4.49 earnings per share for the current year.
Institutional Trading of GeoVax Labs
A number of institutional investors and hedge funds have recently bought and sold shares of GOVX. Geode Capital Management LLC increased its position in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares in the last quarter. Northern Trust Corp acquired a new stake in GeoVax Labs during the 4th quarter worth approximately $29,000. Citadel Advisors LLC acquired a new stake in GeoVax Labs during the 4th quarter worth approximately $104,000. Armistice Capital LLC acquired a new stake in GeoVax Labs during the 1st quarter worth approximately $703,000. Finally, Jane Street Group LLC acquired a new stake in GeoVax Labs during the 1st quarter worth approximately $27,000. Institutional investors and hedge funds own 6.09% of the company’s stock.
GeoVax Labs Company Profile
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
Featured Stories
- Five stocks we like better than GeoVax Labs
- What is an Earnings Surprise?
- Why Pure Storage Is a Core Investment for the AI Era
- Best Stocks Under $10.00
- 2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-Ban
- How to Use the MarketBeat Excel Dividend Calculator
- Unity’s New Ad Solutions Drive Stock to 52-Week High
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.